Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management

Lenvatinib, an oral multikinase inhibitor, requires a structured approach to ensure efficacy while minimizing toxicity. A comprehensive baseline assessment is mandatory before initiating therapy.

1. Pre-Treatment Baseline Evaluation

Prior to starting Lenvatinib, a thorough evaluation is required. This includes blood pressure measurement, urinalysis (including Urine Protein-to-Creatinine Ratio - UPCR), thyroid function tests (TSH, FT4), a complete liver function panel, electrocardiogram (ECG), and echocardiogram (ECHO). Special attention should be paid to pre-existing conditions such as hypertension, cardiovascular disease, or renal impairment to stratify patient risk.

2. Cardiovascular and Renal Monitoring

• Hypertension:​ Hypertension is the most prevalent adverse event. Patients should monitor blood pressure daily at home and adhere to a low-sodium diet. If blood pressure rises, ACE inhibitors, ARBs, or Calcium Channel Blockers (CCBs) should be initiated. In cases of hypertensive crisis (SBP ≥180 mmHg or DBP ≥120 mmHg), Lenvatinib must be withheld pending urgent medical care.

• Proteinuria:​ Monitor UPCR before treatment and every 2–4 weeks during therapy. For Grade 2 proteinuria (UPCR ≥0.5 mg/mg), continue treatment with enhanced monitoring and consider ACEI/ARB therapy. For Grade 3 proteinuria (UPCR ≥2 mg/mg), withhold Lenvatinib until improvement, then resume at a reduced dose.

3. Endocrine and Dermatologic Care

• Hypothyroidism:​ Lenvatinib can inhibit thyroid peroxidase. TSH levels should be checked every 4 weeks. If TSH is elevated, initiate levothyroxine replacement therapy as directed by a physician.

• Hand-Foot Skin Reaction (HFSR):​ Prophylaxis includes frequent application of emollients, wearing loose-fitting shoes, and avoiding friction. For Grade 1–2 reactions, continue therapy with supportive care. For Grade 3 reactions, withhold therapy until resolution to Grade 1 or less, then reduce the dose.

4. Gastrointestinal, Cardiac, and Pharmacological Considerations

• Diarrhea:​ Maintain food hygiene and consume easily digestible meals. Use loperamide for mild-to-moderate diarrhea and ensure adequate hydration. For severe diarrhea (≥7 stools/day), hospitalization for intravenous hydration and nutritional support is required.

• Cardiac Safety:​ Due to the risk of QT interval prolongation, periodic ECGs and electrolyte (potassium, magnesium) monitoring are essential. Report palpitations or syncope immediately.

• Drug Interactions:​ Lenvatinib is primarily metabolized via CYP3A4. Avoid co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) or inducers (e.g., rifampin, St. John’s Wort). Disclose all medications, including supplements, to your healthcare provider.

5. Patient Empowerment

Maintaining a symptom diary to track blood pressure and adverse events enhances communication with your oncology team and improves long-term outcomes.